Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Context Therapeutics Inc.CNTX · Entity 7406 | Director | June 24, 2026 | June 26, 2026 |
| Kardigan, Inc.KARD · Entity 4569 | Chief Strategy Officer | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Context Therapeutics Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2036-06-23 | Direct | 45,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.
Kardigan, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,640 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 79,640 · Balance 79,640 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 56,338 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 11,643 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F4: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F3: The Ordinary Shares subject to the RSUs vest on January 5, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 15,870 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F4: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F5: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-06 · Disposition to issuer · Disposed 22,997 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F4: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F6: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-10-06 · Disposition to issuer · Disposed 15,281 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F7: The Ordinary Shares subject to the PSUs (as defined in footnote 8 to this Form 4) vest on January 5, 2024. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-10-06 · Disposition to issuer · Disposed 5,816 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F7: The Ordinary Shares subject to the PSUs (as defined in footnote 8 to this Form 4) vest on January 5, 2024. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-10-06 · Disposition to issuer · Disposed 34,928 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F7: The Ordinary Shares subject to the PSUs (as defined in footnote 8 to this Form 4) vest on January 5, 2024. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-10-06 · Disposition to issuer · Disposed 4,761 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F9: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-10-06 · Disposition to issuer · Disposed 14,282 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F10: The Ordinary Shares subject to the PSUs vest on January 5, 2025. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-10-06 · Disposition to issuer · Disposed 23,806 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F10: The Ordinary Shares subject to the PSUs vest on January 5, 2025. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-10-06 · Disposition to issuer · Disposed 11,499 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F11: The Ordinary Shares subject to the PSUs vest on January 5, 2026. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-10-06 · Disposition to issuer · Disposed 5,749 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F12: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-10-06 · Disposition to issuer · Disposed 5,749 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F12: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F3: The Ordinary Shares subject to the RSUs vest on January 5, 2024.
F4: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme.
F5: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022.
F6: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.
F7: The Ordinary Shares subject to the PSUs (as defined in footnote 8 to this Form 4) vest on January 5, 2024.
F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration.
F9: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.
F10: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
F11: The Ordinary Shares subject to the PSUs vest on January 5, 2026.
F12: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2022 Filed Jan 6, 2022 21:02 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 21,710 | $101.84 | $2,210,946.40 |
DisclosureSEC source: 0001209191-22-002297 · doc4.xml · nonDerivative · entry 2 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,959 Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 21:02 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 48,839 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-002297 · doc4.xml · nonDerivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 21:02 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 23,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002297 · doc4.xml · derivative · entry 7 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,805 Underlying: Ordinary Shares · 23,805 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F7 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. F7 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 18:35 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 1,525 | $100.00 | $152,500.00 |
DisclosureSEC source: 0001209191-21-068601 · doc4.xml · nonDerivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,830 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,251 | $0.00 Strike: $29.52 | $0.00 |
DisclosureSEC source: 0001209191-21-063201 · doc4.xml · derivative · entry 8 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,251 Underlying: Ordinary Shares · 23,251 shares Expires 2029-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 7,264 | $115.51 | $839,064.64 |
DisclosureSEC source: 0001209191-21-063201 · doc4.xml · nonDerivative · entry 7 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,355 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 2,728 | $114.49 | $312,328.72 |
DisclosureSEC source: 0001209191-21-063201 · doc4.xml · nonDerivative · entry 6 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,619 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.24 to $115.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 5,650 | $113.54 | $641,501.00 |
DisclosureSEC source: 0001209191-21-063201 · doc4.xml · nonDerivative · entry 5 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,347 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.07 to $114.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 2,706 | $112.44 | $304,262.64 |
DisclosureSEC source: 0001209191-21-063201 · doc4.xml · nonDerivative · entry 4 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,997 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.00 to $112.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 6,336 | $111.47 | $706,273.92 |
DisclosureSEC source: 0001209191-21-063201 · doc4.xml · nonDerivative · entry 3 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,703 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.005 to $111.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 5,484 | $110.64 | $606,749.76 |
DisclosureSEC source: 0001209191-21-063201 · doc4.xml · nonDerivative · entry 2 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.985 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 23,251 | $29.52 | $686,369.52 |
DisclosureSEC source: 0001209191-21-063201 · doc4.xml · nonDerivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:31 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 12,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062706 · doc4.xml · derivative · entry 3 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,421 Underlying: Ordinary shares · 12,421 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The shares subject to the restricted stock units vest in three equal annual installments, beginning November 1, 2020. F2 · derivative.expiration_date: The shares subject to the restricted stock units vest in three equal annual installments, beginning November 1, 2020. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:31 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 5,503 | $118.29 | $650,949.87 |
DisclosureSEC source: 0001209191-21-062706 · doc4.xml · nonDerivative · entry 2 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,272 Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:31 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 12,421 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-062706 · doc4.xml · nonDerivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,250 | $0.00 Strike: $29.52 | $0.00 |
DisclosureSEC source: 0001209191-21-055769 · doc4.xml · derivative · entry 4 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,502 Underlying: Ordinary Shares · 23,250 shares Expires 2029-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 496 | $108.26 | $53,696.96 |
DisclosureSEC source: 0001209191-21-055769 · doc4.xml · nonDerivative · entry 3 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,354 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 22,754 | $107.83 | $2,453,563.82 |
DisclosureSEC source: 0001209191-21-055769 · doc4.xml · nonDerivative · entry 2 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,850 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.235 to $108.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 23,250 | $29.52 | $686,340.00 |
DisclosureSEC source: 0001209191-21-055769 · doc4.xml · nonDerivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 16:26 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 17,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048790 · doc4.xml · derivative · entry 3 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,418 Underlying: Ordinary Shares · 17,418 shares Expires not disclosed F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 16:26 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 3,858 | $102.50 | $395,445.00 |
DisclosureSEC source: 0001209191-21-048790 · doc4.xml · nonDerivative · entry 2 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,354 Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 16:26 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 8,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048790 · doc4.xml · nonDerivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,212 F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F2 · balance_after: Includes 762 ordinary shares of the Issuer acquired by the reporting person on June 1, 2021 pursuant to an employee stock purchase program. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 17,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012414 · doc4.xml · derivative · entry 4 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,416 Underlying: Ordinary Shares · 17,416 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F3 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 4,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012414 · doc4.xml · derivative · entry 3 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,718 Underlying: Ordinary Shares · 4,718 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 1,045 | $87.17 | $91,092.65 |
DisclosureSEC source: 0001209191-21-012414 · doc4.xml · nonDerivative · entry 2 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,742 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 2,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012414 · doc4.xml · nonDerivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,787 F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Disposition to issuerRestricted Stock Units (RSU) · Derivative | 14,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002421 · doc4.xml · derivative · entry 4 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,028 Underlying: Ordinary Shares · 14,513 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F2 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 6,526 | $73.28 | $478,225.28 |
DisclosureSEC source: 0001209191-21-002421 · doc4.xml · nonDerivative · entry 2 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,429 Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 14,513 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-002421 · doc4.xml · nonDerivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 34,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002421 · doc4.xml · derivative · entry 3 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,928 Underlying: Ordinary Shares · 34,928 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F2 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 16:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 12,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056623 · doc4.xml · derivative · entry 3 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,842 Underlying: Ordinary shares · 12,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The shares subject to the restricted stock units vest in three equal annual installments, beginning November 1, 2020. F3 · derivative.expiration_date: The shares subject to the restricted stock units vest in three equal annual installments, beginning November 1, 2020. Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 16:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 5,503 | $74.93 | $412,339.79 |
DisclosureSEC source: 0001209191-20-056623 · doc4.xml · nonDerivative · entry 2 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,442 Read SEC document |
| November 01, 2020 Filed Nov 3, 2020 16:25 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 12,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-056623 · doc4.xml · nonDerivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: Includes 1,525 ordinary shares of the Issuer acquired by the reporting person on June 1, 2020 pursuant to an employee stock purchase program. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 18:20 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 43,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002342 · doc4.xml · derivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,541 Underlying: Ordinary Shares · 43,541 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F2 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 17:04 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 37,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055269 · doc4.xml · derivative · entry 2 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,262 Underlying: Ordinary shares · 37,262 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The shares subject to the restricted stock units shall vest in three equal annual installments, beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 17:04 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantStock Option (Right to Buy) · Derivative | 69,752 | $0.00 Strike: $29.52 | $0.00 |
DisclosureSEC source: 0001209191-19-055269 · doc4.xml · derivative · entry 1 Pasternak Andy · CIK 0001792746 · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,752 Underlying: Ordinary shares · 69,752 shares Expires 2029-10-31 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in three equal annual installments, beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.